THOUSAND OAKS, Calif. The board of directors of biotech giant Amgen has appointed Robert Bradway as president and COO, Amgen said Monday.
Bradway has served as the company’s EVP and CFO since April 2007, having begun working for the company as VP operations strategy in 2006. Before Amgen, he was a managing director at Morgan Stanley in London and supervised the company’s banking department and corporate finance activities in Europe.
In his new position at Amgen, Bradway will be responsible for the company’s global commercial operations, manufacturing, strategy and corporate development, information technology, global government affairs and compliance. He will report to chairman and CEO Kevin Sharer.
Amgen also said EVP global commercial operations George Morrow would retire at the end of January 2011. Before then, he will be responsible for preparing the launch of the osteoporosis drug Prolia (denosumab).